Sit Investment Associates Inc. Maintains Position in Halozyme Therapeutics Inc. (HALO)
Sit Investment Associates Inc. held its position in shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,350 shares of the biopharmaceutical company’s stock at the end of the second quarter. Sit Investment Associates Inc.’s holdings in Halozyme Therapeutics were worth $711,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in HALO. IFP Advisors Inc increased its position in shares of Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 8,530 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $155,000. M&T Bank Corp purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $304,000. Kennedy Capital Management Inc. increased its stake in shares of Halozyme Therapeutics by 4.0% in the first quarter. Kennedy Capital Management Inc. now owns 73,681 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 2,818 shares during the last quarter. Finally, ClariVest Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 15.4% in the second quarter. ClariVest Asset Management LLC now owns 91,204 shares of the biopharmaceutical company’s stock valued at $787,000 after buying an additional 12,200 shares during the last quarter. 80.41% of the stock is owned by institutional investors.
Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 2.895% during trading on Thursday, reaching $10.565. 1,158,844 shares of the company were exchanged. Halozyme Therapeutics Inc. has a one year low of $6.96 and a one year high of $18.65. The stock’s market capitalization is $1.35 billion. The firm’s 50 day moving average price is $11.23 and its 200-day moving average price is $10.12.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. The business earned $33.30 million during the quarter, compared to analyst estimates of $29.94 million. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. Halozyme Therapeutics’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.02 EPS. On average, equities research analysts predict that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current year.
HALO has been the subject of several recent analyst reports. Piper Jaffray Cos. upped their target price on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, September 16th. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $16.11.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.